Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Zhang et al. discuss how artificial intelligence (AI) can be used to optimize clinical trial design and potentially boost the success rate of clinical trials. AI has unparalleled potential to leverage real-world data and unlock valuable insights for innovative trial design.
Ivancovsky-Wajcman et al. outline the need for a holistic preventive hepatology approach, involving social nutrition and social prescribing, to address the public health threat of metabolic dysfunction-associated steatotic liver disease (MASLD). They argue that this will facilitate individuals’ engagement in behavioural modifications to treat MASLD.
Macharia et al. discuss a Communications Medicine article on global healthcare accessibility and the impact of the COVID-19 pandemic. They outline strengths in the comprehensive approach taken to studying revealed versus potential spatial accessibility, plus some limitations and wider context with which the results can be interpreted.
Pallett et al. discuss the impact of human conflict on development of antimicrobial resistance. They overview approaches to limit the spread of antimicrobial resistance, using the ongoing conflict in Ukraine as an example of the challenges and opportunities.
Kooman outlines the findings of a Communications Medicine article on deep learning-based detection of chronic kidney disease using ECGs. The author interprets the study’s findings in light of its limitations and outlines key considerations in the clinical implementation of such an approach.
Schattenberg et al. outline discussions from a recent workshop on NAFLD care and advocate for a multidisciplinary approach to managing this complex and multifactorial disease. The authors highlight gaps in current models of care and make recommendations on optimising a multistakeholder approach in steatotic liver diseases.
